Innovative Disruption in the World of Neuromuscular Blockade

Anesthesiology

Volumn 126, Issue 1, 2017, Pages 12-15

  Naguib, Mohamed ^a   Johnson, Ken B ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDROPHONIUM; NEOSTIGMINE; SUGAMMADEX; NEUROMUSCULAR BLOCKING AGENT;

ANAPHYLAXIS; CLINICAL TRIAL; DRUG INTERACTION; DRUG USE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERSENSITIVITY; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR MONITORING; PHARMACOECONOMICS; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; DOSE RESPONSE; NEUROMUSCULAR JUNCTION;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR JUNCTION; NEUROMUSCULAR NONDEPOLARIZING AGENTS;

EID: 85006055050     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0000000000001410     Document Type: Review

References (17)

1. Brull SJ, Kopman AF: Current status of neuromuscular reversal and monitoring: Challenges and opportunities. Anesthesiology 2017; 126:173-90
2. Zwiers A, van den Heuvel M, Smeets J, Rutherford S: Assessment of the potential for displacement interactions with sugammadex: A pharmacokinetic-pharmacodynamic modelling approach. Clin Drug Investig 2011; 31:101-11
3. U.S. Food and Drug Administration: FDA approves Bridion to reverse effects of neuromuscular blocking drugs used during surgery: Available at: http://www. fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm477512.htm?source=govdelivery&utm-medium=email&utm-source=govdelivery. 2015. Accessed May 11, 2016
4. U.S. Food and Drug Administration Advisory Committee: Sugammadex Injection. NDA 22225: Advisory Committee Briefing Materials. Merck Sharp &Dohme Corporation, 2015. Available at: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/ UCM470718.pdf. 2015. Accessed May 11, 2016
5. Kotake Y, Ochiai R, Suzuki T, Ogawa S, Takagi S, Ozaki M, Nakatsuka I, Takeda J: Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block. Anesth Analg 2013; 117:345-51
6. Batistaki C, Tentes P, Deligiannidi P, Karakosta A, Florou P, Kostopanagiotou G: Residual neuromuscular blockade in a real life clinical setting: Correlation with sugammadex or neostigmine administration. Minerva Anestesiol 2016; 82:550-8
7. U.S. Food and Drug Administration: Rocuronium Package Insert. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/ label/2008/078717s000lbl.pdf. 2008. Accessed May 11, 2016
8. Cammu G, De Witte J, De Veylder J, Byttebier G, Vandeput D, Foubert L, Vandenbroucke G, Deloof T: Postoperative residual paralysis in outpatients versus inpatients. Anesth Analg 2006; 102:426-9
9. Naguib M, Brull SJ, Arkes HR: Reasoning of an anomaly: Residual block after sugammadex. Anesth Analg 2013; 117:297-300
10. Naguib M, Kopman AF, Lien CA, Hunter JM, Lopez A, Brull SJ: A survey of current management of neuromuscular block in the United States and Europe. Anesth Analg 2010; 111:110-9
11. Grol R, Grimshaw J: From best evidence to best practice: Effective implementation of change in patients' care. Lancet 2003; 362:1225-30
12. Baillard C, Clec'h C, Catineau J, Salhi F, Gehan G, Cupa M, Samama CM: Postoperative residual neuromuscular block: A survey of management. Br J Anaesth 2005; 95:622-6
13. Todd MM, Hindman BJ, King BJ: The implementation of quantitative electromyographic neuromuscular monitoring in an academic anesthesia department. Anesth Analg 2014; 119:323-31
14. U.S. Food and Drug Administration Advisory Committee: Schering-Plough Sugammadex NDA 22-225: Available at: http://www. fda.gov/ohrms/dockets/ac/08/slides/2008-4346s1-01-Schering-Plough-corebackup.pdf. 2008. Accessed May 11, 2016
15. Masursky D, Dexter F, Kwakye MO, Smallman B: Measure to quantify the influence of time from end of surgery to tracheal extubation on operating room workflow. Anesth Analg 2012; 115:402-6
16. Bayman EO, Dexter F, Todd MM: Prolonged operative time to extubation is not a useful metric for comparing the performance of individual anesthesia providers. Anesthesiology 2016; 124:322-38
17. Epstein RH, Dexter F, Brull SJ: Cohort study of cases with prolonged tracheal extubation times to examine the relationship with duration of workday. Can J Anaesth 2013; 60:1070-6